## NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE TECHNOLOGY APPRAISAL PROGRAMME

**Equality impact assessment – Guidance development** 

## **STA**

Rucaparib for maintenance treatment of recurrent epithelial ovarian, fallopian tube and peritoneal cancer that has responded to platinum-based chemotherapy [ID1485]

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

## Consultation

1. Have any potential equality issues been identified during the scoping process been addressed by the committee, and, if so, how?

During the scoping process, it was noted that the prevalence of ovarian cancer is higher in women aged 50 and over. However, this is not something that can be addressed in a technology appraisal.

2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these?

No other equality issues have been raised in the submissions.

3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these?

No equality issues were identified by the committee.

4.	Do the recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?	
No.		
5.	Is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?	
No.		
6.	Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?	
Not applicable.		
7.	Have the committee's considerations of equality issues been described in the appraisal consultation determination, and, if so, where?	
Not applicable.		
Approved by Associate Director (name):Janet Robertson  Date: 24 September 2019		

Technology Appraisals: Guidance development Equality impact assessment for the Single Technology Appraisal of Rucaparib for maintenance treatment of recurrent epithelial ovarian, fallopian tube and peritoneal cancer

that has responded to platinum-based chemotherapy [ID1485]

Issue date: November 2019

## Final appraisal determination

(when an ACD issued)

1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the committee addressed these?

No equality issues were raised during consultation.

2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No recommendation makes it more difficult in practice for a specific subgroup to access the technology compared with other groups.

3. If the recommendations have changed after consultation, is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

There is no potential for the recommendations to have an adverse impact on people with disabilities.

4. If the recommendations have changed after consultation, are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 2 and 3, or otherwise fulfil NICE's obligations to promote equality?

Not applicable.

5.	Have the committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?
Not applicable.	

Approved by Associate Director (name): ...Janet Robertson.......

Date: 19 November 2019